Lakefront Biotherapeutics | GLPG - Debt


Lakefront Biotherapeutics reported EUR6.44M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
argenx SE USD 47.16M 4.01M Dec/2025
AstraZeneca USD 33.92B 4.3B Mar/2026
Biogen USD 6.56B 275.1M Mar/2026
Genmab DKK 148M 5M Jun/2025
Gilead Sciences USD 24.94B 5M Dec/2025
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
GRIFOLS EUR 9.57B 746.56M Dec/2025
Hikma Pharmaceutical USD 1.56B 252M Jun/2025
Incyte USD 39.43M 982K Mar/2026
Merck EUR 11.95B 152M Dec/2025
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 47B 11.62B Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sanofi EUR 20.33B 1.43B Dec/2025
UCB EUR 3.03B 12M Dec/2024
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026